Loading clinical trials...
Loading clinical trials...
A Phase 4, Multicenter, Open-label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain a Serum Uric Acid Response
Conditions
Interventions
Pegloticase
Methotrexate (MTX)
Locations
15
United States
University of Alabama at Birmingham (UAB) - Center for Education & Research on Therapeutics of Musculoskeletal Disorders
Birmingham, Alabama, United States
Arizona Arthritis and Rheumatology Associates
Flagstaff, Arizona, United States
Arizona Arthritis and Rheumatology Associates
Glendale, Arizona, United States
Arizona Arthritis and Rheumatology Associates
Mesa, Arizona, United States
East Bay Rheumatology Medical Group
San Leandro, California, United States
Providence St. John's Health Clinic
Santa Monica, California, United States
Start Date
March 8, 2021
Primary Completion Date
August 23, 2022
Completion Date
April 24, 2023
Last Updated
June 27, 2024
NCT07116746
NCT04087720
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions